IVV vs XBI
iShares Core S&P 500 ETF vs SPDR S&P Biotech ETF
- • IVV has the lower expense ratio at 0.03% vs 0.35% for XBI.
- • IVV pays a higher dividend yield (1.11%).
Side-by-side metrics
| Metric | IVV | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.03% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.11% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $870.02B | $10.92B |
YTD return | 11.29% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.97 | 1.01 |
P/E ratio | 24.22 | — |
Last price | $764.72 | $156.41 |
Inception | — | — |
Issuer | iShares | State Street |
IVV top holdings
| AAPL | Apple Inc | 7.70% |
| NVDA | NVIDIA Corp | 7.58% |
| MSFT | Microsoft Corp | 5.93% |
| AMZN | Amazon.com Inc | 3.61% |
| GOOGL | Alphabet Inc Class A | 2.51% |
| AVGO | Broadcom Inc | 2.37% |
| META | Meta Platforms Inc Class A | 2.08% |
| GOOG | Alphabet Inc Class C | 2.02% |
| LLY | Eli Lilly and Co | 1.74% |
| TSLA | Tesla Inc | 1.72% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About IVV
IVV (iShares Core S&P 500 ETF) is Low-cost iShares version of the S&P 500. Managed by iShares, the fund carries $870.0B in assets under management, an expense ratio of 0.03%, a dividend yield of 1.11%. Its largest holding is Apple Inc (AAPL), which represents 7.7% of the portfolio. Real Estate is the fund's largest sector exposure at 1.8%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.